Form 4: REVB CEO Sells Shares for Tax Obligations Post-Split

Revelation Biosciences CEO James Rolke disposed of 8,521 common shares to cover tax withholding obligations following a 1-for-4 reverse stock split.

Summary

• James Rolke, CEO and Director of Revelation Biosciences, Inc. (REVB), disposed of 8,521 shares of common stock.
• The transaction occurred on February 3, 2026, at a weighted average price of $1.86 per share, with individual sales ranging from $1.85 to $1.87.
• This disposition was mandatory, solely to satisfy tax withholding obligations arising from the vesting of restricted stock awards.
• Rolke did not exercise investment discretion regarding this sale.
• All share numbers reported reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.
• Following this transaction, James Rolke beneficially owns 224,853 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was non-discretionary and for tax purposes, which is a common occurrence for executives receiving equity compensation, and does not reflect a change in management's confidence in the company.

Positives

• The underlying event for the sale was the vesting of restricted stock awards, indicating compensation for the executive.
• The transaction was mandatory for tax purposes, not a discretionary sale by the executive, suggesting no loss of confidence.

Negatives

• The CEO's direct beneficial ownership of common stock decreased by 8,521 shares.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that tax-related sales of vested equity awards are a common occurrence for executives, especially following significant corporate actions like a reverse stock split which can impact share price and valuation. This transaction is specific to executive compensation and tax obligations rather than a broader industry trend.

Stakeholder Impact

• Shareholders: The reduction in the CEO's direct ownership is minor relative to total shares outstanding and is for tax purposes, so the direct impact on other shareholders is minimal. The reverse stock split, however, could impact per-share metrics.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request to Revelation Biosciences, Inc., any security holder, or the SEC staff.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by the CEO to cover tax obligations related to vested restricted stock awards. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation and tax planning, thus a 'hold' recommendation is appropriate as it doesn't alter the fundamental investment thesis.

Keywords

Revelation Biosciences, REVB, James Rolke, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock, Reverse Stock Split, CEO